These results are lower than the ORRs observed in recent trials, investigating the diverse anti-MET tyrosine kinase inhibitors within this specific population (range 32–46%) [41-44], and for patients with METex14 skipping in line with effectiveness outcome results from a recently similar non-interventional study on a cohort of patients with advanced NSCLC METex14 [45]. This evidence concerns the gene MET and non-small cell lung carcinoma.